Clinical trial
Sorafenib to Overcome Resistance to Systemic Chemotherapy in…
NCT00414388 · Oncology Specialists, S.C., Other · Completed
Key facts
| NCT number | NCT00414388 |
|---|---|
| Title | Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer |
| Official title | Phase I/II Study to Evaluate the Ability of Sorafenib in Overcoming Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer (AIPC) |
| Lead sponsor | Oncology Specialists, S.C., Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Sorafenib |
| Enrollment | 22 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Mar 1, 2012 |
| First posted | Dec 21, 2006 |
| Last update posted | Apr 7, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: